Haleon (NYSE: HLN) sets January 2026 total voting rights figure

Rhea-AI Filing Summary

Haleon plc has updated its share capital and voting rights information. As at 31 January 2026, the company has issued 8,952,353,648 ordinary shares of £0.01 each, of which 45,557,120 shares are held in treasury. This leaves 8,906,796,528 ordinary shares with voting rights.

Shareholders and others with notification obligations under the FCA's Disclosure Guidance and Transparency Rules are instructed to use the voting-rights figure as the denominator when assessing whether they must report their holdings or changes in their interest in Haleon.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	02 February 2026 - “Total Voting Rights and Capital”

99.1

Haleon plc: Total Voting Rights and Capital

02 February 2026: As at 31 January 2026 the total number of shares issued by Haleon plc ("Haleon" or the "Company") is 8,952,353,648 ordinary shares of £0.01 each, of which 45,557,120 are held as treasury shares.

Therefore, the number of ordinary shares with voting rights is 8,906,796,528 and this figure should be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Notifiable interests in Haleon may be sent to: company.secretary@haleon.com

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: February 02, 2026	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary